The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol

ALBAYRAK G., Korkmaz F. D., Tozcu D., DOĞAN TURAÇLI İ.

JOURNAL OF CELLULAR BIOCHEMISTRY, cilt.120, sa.6, ss.10564-10571, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 120 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1002/jcb.28342
  • Dergi Adı: JOURNAL OF CELLULAR BIOCHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.10564-10571
  • Gazi Üniversitesi Adresli: Evet

Özet

ObjectivesLung cancer stands out as the most common cancer type worldwide. The most common genetic alteration detected in adenocarcinoma patients is KRAS. KRAS mutated patients still cannot get benefit from precision medicine approaches and lack a targeted therapy. Elesclomol is an investigational agent for melanoma and other malignancies. In this study, we evaluated its effect on cellular apoptosis, survival, and metastasis mechanisms on KRAS mutant A549 and Calu-1 cell lines.